An interventional study of LIPI-PROTECT-1 in Hypercholesterolemia / Elevated LDL Cholesterol, sponsored by Institut Pasteur de Lille. Active, not recruiting at 2 sites in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Institut Pasteur de Lille · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Hypercholesterolemia with a site in France — 4 open to participants now, 10 under way, 5 of them phase 3. Hypercholesterolemia · France.
Among the 65 studies in Hypercholesterolemia with a site in France, this one is the 60th largest by enrollment of the 61 interventional ones that give a count, is the only one that started in 2026, is one of 15 with no phase, and was the 65th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →4 of the 65 studies in Hypercholesterolemia with a site in France are open now. Recruiting first, the newest first:
Institut Pasteur de Lille · Sites in France
Ages 18–70 · Healthy volunteers
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 2–18 · Healthy volunteers
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 20 more countries
Ages 6–11
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18–80 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 35 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 300 across the 61 interventional studies, 4,816 across the 4 observational. Of the 53 that completed or were terminated, 29 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 65 have an industry lead sponsor. The 10 most frequent:
Institut Pasteur de Lille is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Institut Pasteur de Lille has 3 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypercholesterolemia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07946458Institut Pasteur de LilleLIPI-PROTECT-1 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP1) | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 65 studies in Hypercholesterolemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-1.
The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.
A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.
The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.
LIPI-PROTECT-1 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.
This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-1 in adults with untreated moderate hypercholesterolemia.
A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-1 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.
The primary objective is to assess the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.
Secondary objectives are to evaluate the effect of LIPI-PROTECT-1 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).
Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.
Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Men and women aged 18-65 years
For women :
If pre-menopausal: effective non-estrogenic* initiated at least 2 cycles prior and maintained throughout the study If : not receiving estrogenic* Hormone Replacement Therapy (HRT)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three tablets of LIPI-PROTECT-1 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers
Dietary Supplement: LIPI-PROTECT-1
All subjects will consume 3 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 tablets in the evening during dinner. If a dose is missed, 1 tablet can be taken at the next dose
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).
Time frame: To baseline at 3 months
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).
Time frame: To baseline at 3 months
To evaluate the effect of LIPI-PROTECT-1 on LDL cholesterol.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on Non HDL cholesterol.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on total cholesterol.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on HDL cholesterol.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on triglycerides.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on non HDL cholesterol/LDL (atherogenic index).
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio).
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on ratio LDL/HDL.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio).
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on ratio total cholesterol/HDL.
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio).
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on fasting blood glucose levels.
Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on weight.
Changes in weight (unit : kilograms) between baseline, V1, and V3.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on Body Mass Index (BMI).
Changes in BMI (weight and height will be combined to report BMI) in kg/m\^2between baseline, V1, and V3.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on waist circumference.
Changes in waist circumference (unit: cm) between baseline, V1, and V3.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on arterial blood pressure
Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3.
Time frame: At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on heart rate
Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3.
Time frame: At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism: ASAT/ALAT, GGT
Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 .
Time frame: At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism : Creatinine, bilirubin
Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3.
Time frame: At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Urea
Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3.
Time frame: At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Creatinine Phophoskinase (CPK)
Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3.
Time frame: At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on Renal metabolism : Lactate Deshydrogenase (LDH)
Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3.
Time frame: At baseline and 3 months
To assess adherence to LIPI-PROTECT-1 consumption by pillbox weighing
Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0).
Time frame: At baseline, 1 month and 3 months
To assess self-reported adherence to LIPI-PROTECT-1 consumption
Adherence assessed through participant self-reporting of supplement consumption and missed doses.
Time frame: At 1 month, 2 months and 3 months
To assess adherence to LIPI-PROTECT-1 consumption by counting returned tablets
Adherence assessed by counting the remaining tablets returned by participants at the end of the study.
Time frame: At 3 months
Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.
Of 134 non-industry interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 4 months is below that.
Counting every sponsor, half of 152 studies reached it within 15 months; a quarter within 6 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Pasteur de Lille